Table 1 Baseline characteristics of the study population (n = 21)
Training group | Control group | Group differences | |
|---|---|---|---|
Number | 13 | 8 | n.s. |
Sex (F/M) | 8/5 | 5/3 | n.s. |
Age (years) | 54 ± 11 | 59 ± 9 | n.s. |
Duration of disease (years) | 19 ± 22 | 21 ± 15 | n.s. |
Allergic asthma | 5/13 | 4/8 | n.s. |
Body mass index (kg/m2) | 23 ± 1.6 | 22 ± 2.1 | n.s. |
VC (L) | 3.4 ± 0.9 | 3.0 ± 0.8 | n.s. |
FVC (L) | 3.3 ± 0.9 | 3.0 ± 1.0 | n.s. |
VC %pred | 89 ± 14% | 80 ± 14% | n.s. |
FEV1 (L) | 2.2 ± 0.8 | 2.0 ± 0.7 | n.s. |
FEV1 %pred | 74 ± 24% | 67 ± 16% | n.s. |
FEV1 / FVC (%) | 0.66 ± 0.092 | 0.66 ± 0.085 | n.s. |
Medication | n.s. | ||
ICS (mg/d) | 0.85 ± 0.4 | 0.8 ± 0.4 | n.s. |
long acting beta agonist | 6/13 | 3/8 | n.s. |
montelukast | 2/13 | 1/8 | n.s. |